pramipexole has been researched along with MPTP Neurotoxicity Syndrome in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boguszewski, PM; Kosson, P; Motyl, J; Przykaza, Ł; Strosznajder, JB | 1 |
| Jackson, MJ; Jenner, P; Olanow, CW; Rose, S; Tayarani-Binazir, KA | 1 |
| Menniti, FS; Ramirez, AD; Wong, SK | 1 |
| Cooper, JM; Haddon, CO; Iravani, MM; Jenner, P; Schapira, AH | 1 |
| Anderson, DW; Bradbury, KA; Schneider, JS | 1 |
| Domino, EF; Kohno, Y; Ni, L; Sasa, M; Zhang, H | 1 |
6 other study(ies) available for pramipexole and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson's disease by activation of sphingosine kinase 1 and Akt kinase.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-Associated Death Protein; Brain; Fingolimod Hydrochloride; Male; Mice; MPTP Poisoning; Neuroprotection; Parkinson Disease; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Pramipexole; Proto-Oncogene Proteins c-akt; Rotarod Performance Test; Tyrosine 3-Monooxygenase | 2018 |
Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Callithrix; Carbidopa; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Levodopa; Male; Motor Activity; MPTP Poisoning; Pramipexole; Time Factors | 2010 |
Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms.
Topics: Animals; Benzothiazoles; Dopamine; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; MPTP Poisoning; Piperazines; Pramipexole; Pyrimidines; Receptors, Dopamine D2; Receptors, Dopamine D3; Thiazoles | 2003 |
Pramipexole protects against MPTP toxicity in non-human primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antioxidants; Benzothiazoles; Callithrix; Cell Count; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Female; Immunohistochemistry; Male; MPTP Poisoning; Pramipexole; Thiazoles; Time Factors; Tyrosine 3-Monooxygenase | 2006 |
Neuroprotection in Parkinson models varies with toxin administration protocol.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antigens, Nuclear; Axons; Benzothiazoles; Biomarkers; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Nerve Degeneration; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Niacinamide; Parkinsonian Disorders; Pramipexole; Substantia Nigra; Tyrosine 3-Monooxygenase | 2006 |
Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Azepines; Basal Ganglia Diseases; Behavior, Animal; Benzazepines; Benzothiazoles; Dopamine Agents; Dopamine Agonists; Drug Interactions; Female; Macaca nemestrina; MPTP Poisoning; Parkinson Disease, Secondary; Pramipexole; Sleep; Thiazoles | 1997 |